YieldMax NVDA Option Income Strategy ETF vs Pfizer Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.66, while Pfizer Inc trades at $27.9 (market cap $158.39B). The key difference: Pfizer Inc pays a 6.19% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Pfizer Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | PFE | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $29.02 |
52-Week Low | $11.58 | $23.60 |
Market Cap | — | $158.39B |
Volume | — | 29,869,932 |
Enterprise Value | — | $209.89B |
Dividend Yield | — | 6.19% |
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.82, down 1.23% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF generates consistent weekly dividends but faces structural limitations in capturing Nvidia's full upside potential. Recent analyst downgrades highlight concerns about declining volatility reducing option income effectiveness and potential NAV erosion despite the attractive 39.7% annualized distribution rate.
The outlook remains cautious as NVDY's strategy sacrifices long-term capital appreciation for income generation. While weekly distributions provide cash flow, the fund's structural cap on upside participation and reliance on Nvidia's volatility create headwinds. Investors seeking pure Nvidia exposure may find better alternatives, while income-focused investors should weigh the high distribution rate against potential principal erosion.
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Trailing returns across standard periods
Latest headlines on both assets
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →